![John Cox](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 7 M $ al 30/09/2026
John G.
Cox is President, Chief Executive Officer & Director at Dyne Therapeutics, Inc. since 2024.
He is Chairman at Minovia Therapeutics Ltd. since 2019.
He serves as Director at Canopy Immuno - Therapeutics Ltd. since 2023 and at Torque Therapeutics, Inc. since 2019.
Former roles include Chief Executive Officer & Director at Repertoire Immune Medicines, Inc. from 2019 to 2022, Chief Executive Officer & Director at Bioverativ, Inc. from 2017 to 2018, Independent Director at Repligen Corp.
from 2013 to 2020, Director at Samsung Bioepis Co., Ltd., Independent Director at Sigilon Therapeutics, Inc. from 2019 to 2023, Principal at Wyeth LLC from 1993 to 2000, EVP-Global Commercial & Technical Operations at Biogen, Inc. from 2016 to 2017, Principal at Covance Biotechnology Services, Inc. in 2003, and Executive Vice President at Biogen Idec New Ventures, Inc. Education includes undergraduate studies at Arizona State University, graduate studies at The California State University, and an MBA from the University of Michigan.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
DYNE THERAPEUTICS INC 0,26 % | 08/09/2026 | 429.507 ( 0,26 % ) | 7 M $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Director Ejecutivo | 25/03/2024 |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Develops immunotherapies to address cancers | Director/Miembro de la Junta | - |
Minovia Therapeutics Ltd.
 Minovia Therapeutics Ltd. BiotechnologyHealth Technology Develops mitochondrial cell therapies for clinical-stage biotechnology company | Presidente | 01/02/2019 |
Canopy Immuno - Therapeutics Ltd.
 Canopy Immuno - Therapeutics Ltd. BiotechnologyHealth Technology Operates as a pre-clinical stage biotech company | Director/Miembro de la Junta | 01/03/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Director/Miembro de la Junta | 11/08/2023 |
Repertoire Immune Medicines, Inc.
 Repertoire Immune Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that engages in immune medicines to prevent, treat and cure cancer | Director Ejecutivo | 06/11/2022 |
| REPLIGEN CORPORATION | Director/Miembro de la Junta | 13/05/2020 |
| BIOVERATIV INC | Director Ejecutivo | 01/01/2018 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2017 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 16 |
|---|---|
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceuticals, vaccines & biotechnology products | Health Technology |
Repligen Corp.
 Repligen Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures biologic drugs | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Arizona State University
 Arizona State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The California State University
 The California State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Samsung Bioepis Co., Ltd.
 Samsung Bioepis Co., Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes biopharmaceuticals | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Develops immunotherapies to address cancers | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that engages in discovery, research, development and commercialization of therapies for hemophilia & blood disorders | Health Technology |
Sigilon Therapeutics, Inc.
 Sigilon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics and functional cures for patients with chronic diseases | Health Technology |
Dyne Therapeutics, Inc.
 Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. BiotechnologyHealth Technology Develops mitochondrial cell therapies for clinical-stage biotechnology company | Health Technology |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that engages in immune medicines to prevent, treat and cure cancer | Health Technology |
Canopy Immuno - Therapeutics Ltd.
Canopy Immuno - Therapeutics Ltd. BiotechnologyHealth Technology Operates as a pre-clinical stage biotech company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
